

Rec'd PCT/PTD 14 AUG 2001

#4A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Szardenings *et al.*

Appl. No. 09/674,733

U.S. Nat'l Phase of PCT/GB99/01388

I.A. Filing Date: May 5, 1999

For: **Melanocortin 1 Receptor Selective Compounds**

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 1085.0050000/RWE/ALS

Preliminary Amendment Under 37 C.F.R. §1.121(a)

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants submit the following Amendment under 37 C.F.R. §1.121(a) and Remarks.

This Amendment is provided in the following format:

(A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;

(B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R.

§ 1.111 and MPEP 714; and

(C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

RECEIVED
17 AUG 2001
Legal Staff
International Division